Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
TREACE MEDICAL CONCEPTS, INC. (TMCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Forward Looking Statements and Other Cautions This",
"Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries PONTE VEDRA, Fla. – June 1, 2023—Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today announced that it has signed an asset purchase agreement to acquire certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D , a medical technology company offering pre-operative planning and patient-specific guides designed to deliver accurate surgical correction of deformities customized to the patient’s unique foot anatomy, for a purchase price of $20 million in an upfront cash payment, with up to $10 million in potential milestone payments. Using patient CT scan data, RPM-3D applies innovative s..." |
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Treace Medical Concepts Reports First Quarter 2023 Financial Results PONTE VEDRA, Fla. – May 8, 2023 — Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today reported financial results for the first quarter ended March 31, 2023. Recent Highlights: • Revenue of $42.2 million in the first quarter of 2023, a 45% increase over the same period last year. • Blended average revenue per Lapiplasty® procedure kit sold was $6,244, a 13% increase over the same period last year and a 6% increase sequentially. • Gross margin of 80.9% in the first quarter 2023. • First quarter revenue contribution from direct sales channel, the industry’s only direct bunion-focused salesforce, increased to 79..." |
|
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/04/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
5
| TIMBIE THOMAS E (Director) has filed a Form 5 on TREACE MEDICAL CONCEPTS, INC. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.9% stake in Treace Medical Concepts Inc. |
| 02/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/07/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Treace Medical Concepts Reports Second Quarter 2022 Financial Results PONTE VEDRA, Fla. – August 9, 2022—Treace Medical Concepts, Inc. , a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus , today reported financial results for the second quarter ended June 30, 2022. Recent Highlights: • Revenue of $30.0 million in the second quarter 2022, a 45% increase over the same period last year. Blended average revenue per case increased 5% to over $5,700 from the same period last year. • Gross margin of 81.1% in the second quarter 2022, an increase of 20 basis points from the same period last year. • Second quarter revenue contribution from direct sales channel, the industry’s only direct bunion-focused salesforce, was 68% of sale..." |
|
| 05/23/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob... |
| 04/04/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|